Advanced Proteome Therapeutics Corporation
APCH.V
TSX
| 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -213.21% | -418.65% | -227.32% | -201.46% | -109.24% |
| Depreciation & Amortization | -222.22% | -900.00% | -1,600.00% | -528.57% | -134.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.84% | 26.24% | 36.43% | 44.54% | 30.88% |
| Operating Income | -8.84% | -26.24% | -36.43% | -44.54% | -30.88% |
| Income Before Tax | -360.10% | -262.52% | 67.15% | 131.12% | 137.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -360.10% | -262.52% | 67.15% | 131.12% | 137.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 23.41% | 55.18% | 75.68% | 88.93% | 39.78% |
| Net Income | -306.95% | -376.98% | 84.58% | 141.40% | 145.16% |
| EBIT | -8.84% | -26.24% | -36.43% | -44.54% | -30.88% |
| EBITDA | -9.00% | -26.26% | -36.43% | -44.47% | -30.65% |
| EPS Basic | -290.91% | -57.93% | 91.48% | 133.06% | 135.77% |
| Normalized Basic EPS | -151.19% | -38.61% | 100.00% | 136.95% | 137.42% |
| EPS Diluted | -290.91% | -57.93% | 91.48% | 133.06% | 135.77% |
| Normalized Diluted EPS | -151.19% | -38.61% | 100.00% | 136.95% | 137.42% |
| Average Basic Shares Outstanding | 4.37% | 10.22% | 17.03% | 24.93% | 36.63% |
| Average Diluted Shares Outstanding | 4.37% | 10.22% | 17.03% | 24.93% | 36.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
